ATHA.Athira Pharma, INC

4/A: Athira Pharma CEO Mark Litton Corrects Stock Option Details in Amended SEC Filing

Sentiment:

SEC Filing Amendment

📋All filings for Athira Pharma, INC
🔒Login to Follow

Mark Litton, CEO of Athira Pharma, files an amended SEC Form 4 to correct the exercise price of a stock option granted on October 3, 2024.

Summary

  • Mark Litton, the President and CEO of Athira Pharma, filed an amended Form 4 with the SEC.
  • The amendment corrects the exercise price of a stock option granted to Litton on October 3, 2024.
  • The original filing incorrectly reported the exercise price as $0.4499, while the corrected price is $0.4257.
  • The stock option grants Litton the right to buy 325,000 shares of Athira Pharma common stock.
  • One-third of the shares will vest on each of December 31, 2024, June 30, 2025, and December 31, 2025, contingent upon Litton's continued service.
  • The option expires on October 2, 2034.

Sentiment

Score: 6

Explanation: The document is a routine correction of an SEC filing, indicating standard corporate governance practices. It doesn't inherently suggest positive or negative sentiment, but rather a neutral procedural update.

Industry Context

Stock options are a common form of executive compensation in the pharmaceutical industry, used to align management's interests with those of shareholders and incentivize long-term performance.

Stakeholder Impact

  • Shareholders may be interested in the details of executive compensation.
  • Employees may be interested in the details of executive compensation.

Key Dates

DateDescription
10/03/2024Date of the original transaction and amended filing.
12/31/2024First vesting date for one-third of the shares.
06/30/2025Second vesting date for one-third of the shares.
12/31/2025Third vesting date for one-third of the shares.
10/02/2034Expiration date of the stock option.

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.